Loading...
OTCM
LGNXZ
Market cap6.47bUSD
Jun 25, Last price  
0.00USD
Name

Ligand Pharmaceuticals Inc

Chart & Performance

D1W1MN
OTCM:LGNXZ chart
P/E
0.00
P/S
0.00
EPS
6.21
Div Yield, %
—
Shrs. gr., 5y
4.63%
Rev. gr., 5y
10.39%
Revenues
268m
+60.40%
140,960,00012,894,00027,315,00038,940,00023,538,00030,037,00031,388,00048,974,00064,538,00071,914,000108,973,000141,102,000251,453,000120,282,000163,562,000241,544,000196,245,000131,314,000167,133,000268,087,000
Net income
124m
P
-31,743,000281,688,000-98,114,000-1,948,000-12,515,00010,176,000-527,00011,421,00012,024,000257,305,000-1,636,00012,556,000143,321,000629,302,000-2,985,00057,138,000-33,361,00052,154,000-4,032,000124,453,000
CFO
49m
-49.14%
-138,521,000-97,727,000-20,625,000-33,801,000-27,067,000-1,172,000161,00020,690,00020,566,00041,727,00063,001,00093,568,000194,059,000-29,336,00054,586,00078,798,000137,850,00049,577,00097,047,00049,359,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Ligand Pharmaceuticals, Inc. functions as a biopharmaceutical firm, primarily focusing on developing and acquiring innovative technologies that empower other pharmaceutical companies in their drug discovery and development processes. Its comprehensive product line features treatments such as evomela, IV voriconazole, duavee, viviant/conbriza, nexterone, and noxafil-IV. The company was established in 1987 by Ronald M. Evans and is headquartered in Jupiter, Florida.
URL
https://www.ligand.com/
IPO date
Nov 18, 1992
Employees
76
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT